Ongoing Pregnancy Rates in Women with Low and Extremely Low AMH Levels. A Multivariate Analysis of 769 Cycles

Background The ideal test for ovarian reserve should permit the identification of women who have no real chance of pregnancy with IVF treatments consequent upon an extremely reduced ovarian reserve. The aim of the current study was to evaluate pregnancy rates in patients with low AMH levels (0.2–1 ng/ml) and extremely low AMH levels (<0.2 ng/ml) and to determine the cumulative pregnancy rates following consecutive IVF treatments. Methods We conducted an historical cohort analysis at a tertiary medical center. Serum AMH levels were measured at initial clinic visit and prior to all following treatment cycles in 181 women (769 cycles) with an initial AMH level ≤1 ng/ml, undergoing IVF-ICSI. Main outcome measures were laboratory outcomes and pregnancy rates. Results Seventy patients undergoing 249 cycles had extremely low AMH levels (≤0.2 ng/ml), whereas 111 patients undergoing 520 cycles had low AMH levels (0.21–1.0 ng/ml). Number of oocytes retrieved per cycle, fertilized oocytes and number of transferred embryos were significantly lower in the extremely low AMH levels group compared to the low AMH levels (P<0.003). Crude ongoing pregnancy rates were 4.4% for both groups of patients. Among 48 cycles of women aged ≥42 with AMH levels of ≤0.2 ng/ml no pregnancies were observed. But, in patients with AMH levels of 0.2–1.0 ng/ml, 3 ongoing pregnancies out of 192 cycles (1.6%) were observed. However, in a multivariate regression analysis adjusted for age and cycle characteristics, no significant differences in ongoing pregnancy rates per cycle between the two groups were evident. Cumulative pregnancy rates of 20% were observed following five cycles, for both groups of patients. Conclusions Patients with extremely low AMH measurements have reasonable and similar pregnancy rates as patients with low AMH. Therefore, AMH should not be used as the criterion to exclude couples from performing additional IVF treatments.

[1]  S. Kōzuma,et al.  The significance of serum anti-Müllerian hormone (AMH) levels in patients over age 40 in first IVF treatment , 2013, Journal of Assisted Reproduction and Genetics.

[2]  A. Nyboe Andersen,et al.  Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. , 2013, Fertility and sterility.

[3]  R. Hemi,et al.  What is the optimal threshold of serum Anti-Müllerian hormone (AMH) necessary for IVM treatments? , 2013, Journal of Assisted Reproduction and Genetics.

[4]  W. Yeung,et al.  Role of Baseline Antral Follicle Count and Anti-Mullerian Hormone in Prediction of Cumulative Live Birth in the First In Vitro Fertilisation Cycle: A Retrospective Cohort Analysis , 2013, PloS one.

[5]  S. Nelson Biomarkers of ovarian response: current and future applications. , 2013, Fertility and sterility.

[6]  P. Timms,et al.  Anti-Müllerian hormone as a predictor of pregnancy following IVF. , 2013, Reproductive biomedicine online.

[7]  M. Olovsson,et al.  Antimüllerian hormone levels are strongly associated with live-birth rates after assisted reproduction. , 2013, The Journal of clinical endocrinology and metabolism.

[8]  T. S. Patrelli,et al.  Anti-Müllerian Hormone Serum Values and Ovarian Reserve: Can It Predict a Decrease in Fertility after Ovarian Stimulation by ART Cycles? , 2012, PloS one.

[9]  D. Barad,et al.  Follicle Stimulating Hormone and Anti-Müllerian Hormone per Oocyte in Predicting in vitro Fertilization Pregnancy in High Responders: A Cohort Study , 2012, PloS one.

[10]  S.M. Nelson,et al.  The journey from the old to the new AMH assay: how to avoid getting lost in the values. , 2011, Reproductive biomedicine online.

[11]  D. Barad,et al.  Live birth chances in women with extremely low-serum anti-Mullerian hormone levels. , 2011, Human reproduction.

[12]  D. Seidman,et al.  Couples offered free assisted reproduction treatment have a very high chance of achieving a live birth within 4 years. , 2011, Fertility and sterility.

[13]  Jeff G. Wang,et al.  The association between anti-Müllerian hormone and IVF pregnancy outcomes is influenced by age. , 2010, Reproductive biomedicine online.

[14]  Chun-Chia Huang,et al.  Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles , 2009, Reproductive biology and endocrinology : RB&E.

[15]  D. Barad,et al.  Correlation of antimüllerian hormone and baseline follicle-stimulating hormone levels. , 2009, Fertility and sterility.

[16]  D. Barad,et al.  Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function. , 2009, Fertility and sterility.

[17]  B. Mol,et al.  The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. , 2009, Fertility and sterility.

[18]  S. Nelson,et al.  Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. , 2008, Human reproduction.

[19]  P. Bischof,et al.  Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. , 2008, Fertility and sterility.

[20]  S. Nelson,et al.  Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles--implications for individualization of therapy. , 2007, Human reproduction.

[21]  A. Volpe,et al.  Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. , 2007, Human reproduction.

[22]  L. Nardo,et al.  Anti-Müllerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: Relationship to lifestyle factors, chronological age and reproductive history , 2007, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[23]  G. Zielhuis,et al.  Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. , 2007, Fertility and sterility.

[24]  B. Mol,et al.  A systematic review of tests predicting ovarian reserve and IVF outcome. , 2006, Human reproduction update.

[25]  Jeff G. Wang,et al.  Elevated serum müllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. , 2006, Fertility and sterility.